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Swine  are  often  asymptomatic  carriers  of  Salmonella  spp.,  a leading  cause  of  human  bacterial  food-
borne disease.  Vaccination  against  Salmonella  is effective  for protecting  animal  health  and  enhancing
food  safety.  However,  with  >2500  Salmonella  serovars,  current  vaccines  for  swine  offer  limited  cross-
protection  against  heterologous  serovars.  Also,  existing  vaccines  can  interfere  with  surveillance  programs
that monitor  the  Salmonella  status  of  swine  herds.  To  overcome  Salmonella  vaccine  limitations,  we  ratio-
nally  designed  and  constructed  an attenuated  Salmonella  enterica  serovar  Typhimurium  vaccine  (BBS 866)
by deleting  multiple  small  regulatory  RNA  (sRNA)  genes  (omrA,  omrB,  rybB,  micA,  and  invR)  in combination
with  an  rfaH  mutation.  We  vaccinated  swine  intranasally  at 3-weeks  of  age  with  PBS  (mock-vaccinated),
BBS  866 or  BBS  202 (S. Typhimurium  rfaH,  Bearson  et  al.,  Front  Vet  Sci 2014;1:9.)  and  challenged  at
7-weeks  of age  with  virulent  S. Choleraesuis,  a swine  pathogen.  Vaccination  with  BBS  866 enhanced
protection  against  S. Choleraesuis  by  signiﬁcantly  limiting  the duration  of fever,  weight  loss,  the  levels
of circulating  INF ,  and the total  number  of  swine  with S. Choleraesuis  septicemia.  Vaccination  with
either  BBS  866  or BBS  202  signiﬁcantly  reduced  S. Choleraesuis  colonization  of  both  systemic  (spleen  and
liver)  and  gastrointestinal  (Peyer’s  Patch,  Ileocecal  lymph  nodes,  and  cecum)  tissues.  Similar to our  earlier
report for BBS  202,  the  BBS  866  vaccine  strain  can be used  in swine  without  compromising  the  differen-
tiation  of  infected  from  vaccinated  animals  (DIVA).  Therefore,  the  attenuated  S. Typhimurium  BBS  866
strain,  containing  mutations  in  rfaH  and  multiple  sRNAs,  addresses  the  limitations  of  current  Salmonella
vaccines  by  providing  cross-protection  against  Salmonella  serovars  in  swine  without  interfering  with
established  monitoring  programs  for  Salmonella  surveillance.
Published  by  Elsevier  Ltd.  This is  an  open  access  article  under  the CC  BY license  (http://. Introduction
With over 50% of U.S. swine farms testing Salmonella posi-
ive [1], Salmonella is an animal production issue that can result
n a food safety problem. While infection with some Salmonella
erovars can cause disease (such as Choleraesuis in swine), typ-
cally food animals are asymptomatically colonized, resulting in
athogen transmission and environmental contamination [2]. Fur-
hermore, unrecognized Salmonella colonization can exacerbate
econdary illnesses during other bacterial and viral infections and
ave negative economic consequences for producers [3,4]. A viable
ntervention option for the reduction of Salmonella spp. in food ani-
als is vaccination. However, controlling Salmonella spp. in food
nimals is hindered by the existence of over 2500 serovars, and
ost serovars have a broad host range and ubiquitous distribution.
∗ Corresponding author. Tel.: +1 5152940209; fax: +1 5152941209.
E-mail address: brad.bearson@ars.usda.gov (B.L. Bearson).
ttp://dx.doi.org/10.1016/j.vaccine.2016.01.036
264-410X/Published by Elsevier Ltd. This is an open access article under the CC BY licencreativecommons.org/licenses/by/4.0/).
Current vaccines on the market exhibit efﬁcacy but have limited
cross-protection due to the serovar-speciﬁc, immunodominant
antigens of Salmonella.  Furthermore, many of the Salmonella vac-
cines interfere with herd level monitoring programs for Salmonella
due to antibody production against lipopolysaccharide (LPS) [5,6].
Thus, goals for our live, attenuated vaccine are cross-protection
against Salmonella serovars while achieving DIVA vaccine status
(differentiation of infected from vaccinated animals).
In Bearson et al. [7], our research group characterized the
reduction of Salmonella fecal shedding, intestinal colonization and
disease severity using an attenuated rfaH mutant of Salmonella
enterica serovar Typhimurium (S. Typhimurium) for protection
against the parental, wild-type strain. In the current study, we
describe the additional mutation of ﬁve small RNA genes that neg-
atively regulate conserved outer membrane proteins (OMPs). The
rationale of the vaccine design is reduction of the highly variable,
immuno-dominant LPS and enhancement of immuno-conserved
OMPs. We  demostrate cross-protection against systemic disease
with virulent S. enterica serovar Choleraesuis, a swine pathogen, by
se (http://creativecommons.org/licenses/by/4.0/).
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omparing mock-vaccinated pigs with pigs vaccinated with either
he rfaH mutant (BBS 202) or the omrA, omrB, rybB, micA, invR, rfaH
utant (BBS 866) of S. Typhimurium.
. Materials and methods
.1. Bacterial strains and construction of the S. Typhimurium
accine
The bacterial strains used in this study are listed in Supple-
entary Table 1. Recombineering and classical genetic techniques
ere used to construct the S. Typhimurium mutants as previously
escribed [8]. Oligonucleotide primer pairs for construction of gene
nockouts are listed in Supplementary Table 2 and were used to PCR
mplify the oBBI 92/93 neo cassette to construct linear knockout
ragments.
.2. Swine trial
Thirty crossbred, conventionally raised piglets from four
almonella-fecal-negative sows were weaned at 12 days of age
nd shipped to the National Animal Disease Center, Ames, IA,
SA. Siblings from each litter were divided and raised in three
solation rooms (n = 10 pigs/room). Piglets tested fecal-negative
or Salmonella spp. twice over a 2-week period using bacterio-
ogical culture with selective enrichment [9]. At three-weeks of
ge, piglets received an intranasal administration of 1 ml  of PBS
mock-vaccinated) or PBS containing 1 × 109 CFU of live attenu-
ted S. enterica serovar Typhimurium strains BBS 202 (rfaH::neo)
r BBS 866 (rybB omrAB micA invR rfaH::neo). The body
emperature was  monitored at 0, 1, 2, 3, and 7 days following vac-
ination using a rectal thermometer (see Supplementary Table 3:
imetable for Swine Procedures and Sampling during the Vaccine
rial). At seven-weeks of age, all pigs were intranasally challenged
ith 1 ml  of PBS containing 1 × 109 CFU of wild-type S. enterica
erovar Choleraesuis 3246 (SX118). Body temperature and IFN
in a subset of pigs) were monitored at 0, 1, 2, 3, and 7 days follow-
ng challenge. Swine body weight was determined at day 0 (prior
o challenge) and day 7 post-challenge with S. Choleraesuis. The
verage daily gain was calculated by subtracting the weight at day
 from the weight at day 7 and dividing by 7.
.3. Sample collection and processing
Blood samples were obtained via the porcine jugular vein at the
ndicated time points following vaccination and challenge (Sup-
lementary Table 3). Blood culture isolation of S. Choleraesuis was
erformed using the ISOSTAT® System (Inverness Medical, Prince-
on, N.J.) with recovery on modiﬁed XLT-4 medium (see below).
t 7 days post-challenge, all pigs were euthanized and necropsies
erformed to obtain tissue samples from the liver, spleen, ton-
il and the intestinal tract (ileal Peyer’s Patches, ileocecal lymph
odes, and cecum) for quantitative and qualitative Salmonella cul-
ure analysis as previously described with slight modiﬁcation [10].
ne hundred microliters of each homogenized tissue (one gram
f tissue combined with two ml  of PBS) was aliquoted onto XLT-
 media containing antibiotics to enhance selection. BBS 202 and
BS 866 were grown on XLT-4 medium containing kanamycin and
alidixic acid with full strength tergitol (4.6 ml/l). S. Choleraesuis
3246 is a weak H2S producer on XLT-4 medium containing full
trength tergitol (data not shown); therefore, the tergitol concen-
ration was reduced to 25% of the normal level (1.15 ml/l). The
eduction in tergitol concentration allowed 3246 to produce black
olonies due to H2S production while providing growth inhibition
o non-Salmonella microorganisms. To provide additional selection4 (2016) 1241–1246
for S. Choleraesuis, streptomycin (100 g/ml) was included in the
modiﬁed XLT-4 medium.
2.4. Interferon gamma (INF) analysis
Determination of serum IFN levels following S. Choleraesuis
challenge was performed using the Porcine IFN gamma  ELISA Kit
(Pierce Biotechnology, Rockford, IL) per the manufacturer’s instruc-
tions.
2.5. IDEXX HerdChek swine Salmonella antibody assay
The IDEXX HerdChek Swine Salmonella Test Kit (IDEXX Europe
B.V., Hoofddorp, Netherlands) was  used to determine the pres-
ence of serum antibody to LPS antigen derived from Salmonella
serogroups B, C1, and D as previously indicated [7]. An S/P ratio
of ≥0.25 was considered positive while <0.25 was  considered neg-
ative.
2.6. Statistical analysis
All statistical analyses were performed in GraphPad Prism 5.01
(GraphPad Software, Inc., La Jolla, CA). Statistical analysis of body
temperatures within each treatment group was  performed using a
Repeated Measures ANOVA with a Dunnett’s Multiple Comparison
Test. Analysis of the combined mean body temperature, aver-
age daily weight gain, and the Salmonella Log10 CFU/g tissue was
performed using a One-way ANOVA with a Tukey’s Multiple Com-
parison Test. Statistical analysis of IFN data was performed using
an Unpaired t-test. A Two-way ANOVA followed by Bonferroni’s
Multiple Comparison Test was  performed for statistical analysis
comparing body temperatures between groups. Contingency anal-
ysis of blood culture data, the prevalence of S. Choleraesuis in
selected tissues, and IDEXX results for the mock- and BBS 866-
vaccinated groups at 3-weeks of age was  performed using the
Fisher’s exact test.
3. Results
A rationally designed S. Typhimurium vaccine strain (BBS 866),
containing multiple genetic mutations (rybB omrAB micA
invR rfaH::neo), was constructed to enhance host immune pro-
tection against multiple Salmonella serovars. A vaccine trial was
conducted to evaluate protection provided by BBS 866 compared to
BBS 202 (rfaH::neo), a vaccine strain that was previously described
[7]. At three-weeks of age, 10 piglets per group were vaccinated by
intranasal administration of PBS (mock-vaccinated) or PBS contain-
ing 1 × 109 CFU of the S. Typhimurium strains BBS 202 or BBS 866.
Body temperature (fever) was  monitored at 0, 1, 2, 3, and 7 days
following vaccination, and neither BBS 202 nor BBS 866 induced a
signiﬁcant increase in the swine body temperatures following vac-
cine administration compared to mock-vaccinated swine (Fig. 1).
These data are similar to our previous results with BBS 202 and
indicate that both BBS 202 and BBS 866 are attenuated for virulence.
At seven-weeks of age (4 weeks following vaccination), all pigs
(n = 10/group) were intranasally challenged with PBS containing
1 × 109 CFU of wild-type S. Choleraesuis. Body temperature was
monitored at 0, 1, 2, 3, and 7 days following challenge. A signiﬁcant
increase was observed for both mock-vaccinated (P < 0.001) and the
BBS 202 vaccinated (P < 0.05) swine at day 1 post-challenge com-
pared to day 0 (Fig. 2A); a signiﬁcant increase in body temperature
at day 1 was  not observed in the BBS 866 vaccinated pigs (P > 0.05).
Furthermore, the body temperature at day 1 post-challenge for
the BBS 866 vaccinated swine was  signiﬁcantly lower compared
to both mock-vaccinated (P < 0.01) and the BBS 202 vaccinated
(P < 0.05) swine. At day 2 and 3 post-challenge, a signiﬁcantly
B.L. Bearson et al. / Vaccine 3
Fig. 1. The average body temperature is not increased due to vaccination with either BBS
202  or BBS 866. At 3-weeks of age, swine (n = 10/group) were inoculated with 1 ml  of
PBS (mock-vaccinated) or PBS containing 1 × 109 CFU of S. Typhimurium strains BBS
202  or BBS 866. Body temperature (fever) was  monitored by a rectal thermometer
at  0, 1, 2, 3, and 7 days following vaccination. Statistically signiﬁcant differences
between groups on the individual days are indicated by samples with dissimilar
letters (a vs b).
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Fig. 2. The average body temperature and circulating IFN levels for swine challenged
with S. Choleraesuis. At 7-weeks of age, mock-vaccinated and vaccinated (BBS 202
and BBS 866) swine (n = 10/group) were intranasally challenged with PBS contain-
ing  1 × 109 CFU of wild-type S. Choleraesuis. Body temperature (A) and serum IFN
levels (B) were monitored at 0, 1, 2, 3, and 7 days following challenge. Serum IFN
levels were not determined (nd) for BBS 202-vaccinated swine samples from days
0,  1, and 2 post-challenge with S. Choleraesuis. Statistically signiﬁcant differences
between groups on the individual days are indicated by samples with dissimilar
letters (a vs b).4 (2016) 1241–1246 1243
elevated body temperature was  measured in all S. Choleraesuis
challenged pigs compared to day 0; however, the temperature was
signiﬁcantly lower in the BBS 866 vaccinated swine compared to
the mock-vaccinated (P < 0.05) swine at day 3 post-challenge. By
day 7 post-challenge, a signiﬁcantly lower body temperature was
observed for both the BBS 202 (P < 0.001) and BBS 866 (P < 0.001)
vaccinated pigs compared to the mock-vaccinated swine. Addi-
tionally at day 7 post-challenge, body temperature of only the
mock-vaccinated swine was still signiﬁcantly elevated (P < 0.001)
compared to day 0. The combined mean body temperature at
1, 2, 3, and 7 days post-challenge for BBS 866 vaccinated swine
(39.96 ◦C) was  signiﬁcantly lower than mock-vaccinated swine
(40.72 ◦C; P < 0.001); a signiﬁcant difference was not observed for
the combined mean body temperature of BBS 202 vaccinated pigs
(40.37 ◦C) compared to the other two groups. Similarly, the aver-
age daily weight gain (ADG) for BBS 866 vaccinated swine (0.061 kg)
was signiﬁcantly greater than mock-vaccinated swine (−0.133 kg;
P < 0.01); a signiﬁcant difference was not observed for the ADG  of
BBS 202 vaccinated pigs (0.003 kg; P > 0.05) compared to the other
two groups. The data indicates that vaccination of swine with BBS
866 limited the overall intensity of pyrexia and the duration of ill-
ness while enhancing ADG following challenge with S. Choleraesuis.
A Th1 immune response is generated against viral and intra-
cellular bacterial pathogens and is characterized by production of
the cytokine interferon-gamma (IFN). Analysis of serum IFN lev-
els in S. Choleraesuis challenged swine indicated a signiﬁcantly
lower IFN level in the BBS 866 vaccinated pigs compared to mock-
vaccinated swine at days 3 and 7 post-challenge (P = 0.0345 and
P = 0.0035, respectively; Fig. 2B). The IFN level in the BBS 202 vac-
cinated pigs at days 3 and 7 post-challenge were not signiﬁcantly
lower than mock-vaccinated swine. Together the lower mean body
temperature, average daily gain, and IFN levels at days 3 and 7
post-challenge suggest that disease resolution was  occurring faster
for BBS 866 vaccinated swine compared to BBS 202 and mock-
vaccinated pigs.
Because S. Choleraesuis can cause bacteremia in swine, blood
culture isolation was performed to detect the pathogen in the sys-
temic circulatory system. Blood cultures from a subset of pigs in
all three groups were positive for S. Choleraesuis isolation at days
2, 3, and 7 post-challenge. The blood culture results were ana-
lyzed to determine: (a) the cumulative number of positive blood
cultures over multiple days, (b) the number of positive blood cul-
tures at 7 days post-challenge, and (c) the cumulative number
of pigs with positive blood culture results over time. Cumulative
blood culture results for days 2, 3, and 7 post-challenge indicated a
signiﬁcantly higher number of positive-blood cultures comparing
mock-vaccinated swine (24 samples) to both the BBS 202 (11 sam-
ples; P = 0.0014) and BBS 866 (7 samples; P < 0.0001) vaccinated
pigs (Fig. 3A). Analysis of blood culture results at 7 days post-
challenge indicated that both the BBS 202 vaccinated swine (3 pigs;
P = 0.0198) and the BBS 866 vaccinated pigs (2 pigs; P = 0.0055) had
a signiﬁcantly lower number of positive-blood cultures compared
to mock-vaccinated pigs (9 pigs; Fig. 3B). Analysis of the number
of pigs in each group that were blood culture-positive at any time
point indicates that the cumulative number of blood culture pos-
itive pigs was  signiﬁcantly different comparing mock-vaccinated
to BBS 866 vaccinated pigs (P = 0.0108; Fig. 3C). Therefore, vaccina-
tion with BBS 866 signiﬁcantly reduced the number of pigs with S.
Choleraesuis septicemia compared to mock-vaccinated swine.
At day 7 post-challenge with S. Choleraesuis, necropsies were
performed on all pigs and multiple tissues were obtained for quan-
titative and qualitative bacteriology. The S. Choleraesuis CFU/g of
spleen tissue was  signiﬁcantly lower by ∼2 logs in both the BBS
202 (P < 0.01) and BBS 866 (P < 0.001) vaccinated swine compared
to mock-vaccinated pigs (Fig. 4). In addition, the total number
of pigs from which S. Choleraesuis was isolated from the spleen
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Fig. 3. Vaccination of swine signiﬁcantly reduces the incidence of S. Choleraesuis
recovery from blood cultures following challenge. Contingency analysis of S. Choler-
aesuis recovery from blood cultures (BC) of mock-vaccinated and vaccinated (BBS
202  and BBS 866) pigs for (A) the cumulative number of positive blood cultures at
days 2, 3, and 7 following challenge, (B) the number of positive blood cultures at day
7
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Fig. 4. Vaccination of swine signiﬁcantly reduces colonization of the spleen, liver, and
tonsil following S. Choleraesuis challenge. Analysis of S. Choleraesuis (CFU/g) recovery
from spleen, liver, and tonsil tissue at day 7 following challenge of mock-vaccinated
and  vaccinated (BBS 202 and BBS 866) pigs (n = 10/group). Statistically signiﬁcant
differences are indicated by samples with dissimilar letters (a vs b). The number
of  swine that are S. Choleraesuis culture-positive and -negative from each tissue is
indicated below the graph.
Fig. 5. Vaccination of swine signiﬁcantly reduces colonization of gastrointestinal tissues
following S. Choleraesuis challenge. Analysis of S. Choleraesuis (CFU/g) recovery from
Peyer’s Patch, Ileocecal lymph node (ICLN), and Cecum tissue at day 7 following chal-
lenge of mock-vaccinated and vaccinated (BBS 202 and BBS 866) pigs (n = 10/group). post-challenge, and (C) the cumulative number of pigs with positive blood cul-
ures during the challenge phase. Statistically signiﬁcant differences are indicated
y  samples with dissimilar letters (a vs b).
issue was signiﬁcantly lower for both BBS 202 (4 pigs; P = 0.0108)
nd BBS 866 (3 pigs; P = 0.0031) vaccinated swine compared to
ock-vaccinated pigs (10 pigs; Fig. 4). The S. Choleraesuis CFU/g
f liver tissue was signiﬁcantly lower by >2 logs in both the BBS
02 (P < 0.01) and the BBS 866 (P < 0.01) vaccinated pigs compared
o mock-vaccinated pigs (Fig. 4). The total number of pigs from
hich S. Choleraesuis was isolated from the liver tissue was sig-
iﬁcantly lower for BBS 202 (5 pigs; P = 0.0325) vaccinated swine
ompared to mock-vaccinated pigs (10 pigs; Fig. 4). The S. Choler-
esuis CFU/g of tonsil tissue was signiﬁcantly lower by ∼1.5–2 logs
n both the BBS 202 (P < 0.05) and BBS 866 (P < 0.01) vaccinated
wine compared to mock-vaccinated pigs (Fig. 4). A trend towardsStatistically signiﬁcant differences are indicated by samples with dissimilar letters
(a  vs b). The number of swine that are S. Choleraesuis culture-positive and -negative
from each tissue is indicated below the graph.
signiﬁcance was noted for the total number of pigs from which S.
Choleraesuis was isolated from the tonsil tissue for BBS 866 (4 pigs;
P = 0.0573) vaccinated swine compared to mock-vaccinated pigs (9
pigs; Fig. 4).
For each of the swine gastrointestinal tissues analyzed, a sig-
niﬁcant 1.5–3 log reduction in S. Choleraesuis colonization was
observed for the BBS 202 and BBS 866 vaccinated pigs compared
to the mock-vaccinated swine (Fig. 5). The S. Choleraesuis CFU/g of
Peyer’s Patch, ileocecal lymph node (ICLN), and cecum tissue was
signiﬁcantly lower in both the BBS 202 (P < 0.01; P < 0.001; P < 0.01,
respectively) and BBS 866 (P < 0.05; P < 0.05; P < 0.05, respectively)
vaccinated swine compared to mock-vaccinated pigs.
Bacteriological cultures were performed to determine fecal
shedding and tissue persistence of the vaccine strains following
vaccination with a single dose of either BBS 202 or BBS 866. Vac-
cination of swine with BBS 202 and BBS 866 was  conﬁrmed by
bacteriological culture of feces; all vaccinated swine were culture-
positive at day 1 post-vaccination (Supplementary Table 4). For
BBS 202-vaccinated swine, a subset of pigs were intermittently
B.L. Bearson et al. / Vaccine 3
Fig. 6. Analysis of porcine serum antibodies to Salmonella LPS following Salmonella vac-
cination and challenge of pigs. The number of pigs with serum containing antibodies
to  Salmonella LPS at 3-weeks (vaccination), 5-weeks, 7-weeks (challenge) and 8-
weeks (7 days post-challenge) of age for mock-vaccinated and BBS 866-vaccinated
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Iigs. The percent positive pigs at each time point are shown. All pigs were chal-
enged with S. Choleraesuis at 7-weeks of age. An S/P ratio of ≥0.25 was considered
ositive and <0.25 was  considered negative.
hedding the BBS 202 vaccine strain until the day of necropsy
5 weeks following vaccination). For BBS 866-vaccinated swine,
he last day of fecal shedding of the BBS 866 vaccine strain was
t 21 days (3 weeks) following vaccination (1 week prior to S.
holeraesuis challenge). The only tissue that was  culture-positive at
ecropsy (1 week following S. Choleraesuis challenge) with either
accine strain was the tonsil for a subset of pigs (Supplementary
able 4).
Our previous research demonstrated that vaccination of swine
ith BBS 202 could be used in conjunction with Salmonella moni-
oring programs to differentiate between infected and vaccinated
nimals (DIVA) [7]. To ensure that combining the rfaH mutation
ith multiple sRNA mutations did not compromise the DIVA status
f the vaccine, the IDEXX Swine Salmonella Ab Test was  performed
sing serum from swine vaccinated with BBS 866 compared to
ock-vaccinated pigs. The piglets in this vaccine trial are the off-
pring from four sows, and screening these sows prior to farrowing
etermined that they were not shedding Salmonella in their feces.
owever, serological analysis of sow serum using the IDEXX Swine
almonella Ab Test indicated that 3 of the 4 sows were positive
or antibodies to Salmonella LPS. Upon screening at three-weeks
f age and corresponding to the day of vaccination, a subset of
iglets (from the three Salmonella-antibody-positive sows) in both
he BBS 866-vaccinated and mock-vaccinated groups were positive
S/P ratio ≥0.25) for antibodies to Salmonella LPS (Fig. 6). Although
he number of piglets with antibodies to Salmonella LPS were dif-
erent between the two groups, this difference was  not statistically
igniﬁcant (P = 0.1409). At 7-weeks of age (prior to challenge), the
umber of pigs with serum that contained antibodies to Salmonella
PS had declined over the previous 4 weeks for both BBS 866-
accinated and mock-vaccinated pigs. The decline at 7-weeks of
ge in both groups suggests that the initial detection of antibod-
es to Salmonella LPS in piglet serum is due to maternal antibodies
hat were waning. Moreover, vaccination of pigs with BBS 866 at
-weeks of age did not induce an antibody response against LPS
erived from the Salmonella BBS 866 vaccine. Thus, mutation of
ultiple sRNAs does not compromise the DIVA status of the BBS
66 vaccine strain, and vaccination with BBS 866 should not inter-
ere with the monitoring for herd level prevalence of Salmonella
pp. At 7 days post-challenge with wild-type S. Choleraesuis and
orresponding to 8-weeks of age, serum from 80% of BBS 866-
accinated and 80% of mock-vaccinated pigs was positive in the
DEXX Swine Salmonella Ab Test. This indicates that vaccination4 (2016) 1241–1246 1245
with S. Typhimurium BBS 866 does not inhibit induction of the host
immune response to the LPS antigen(s) present on S. Choleraesuis.
4. Discussion
The goal of our current study was  to create a S. Typhimurium
DIVA vaccine that is cross-protective against other Salmonella
serovars. To accomplish this, additional mutations were combined
with the Salmonella Typhimurium rfaH mutation by deletion of
genes encoding small regulatory RNAs (sRNA). The sRNAs omrA,
omrB, rybB, micA, and invR were selected for deletion in the BBS
866 vaccine strain due to their post-transcriptional regulation of
mRNAs encoding conserved outer membrane proteins (Supple-
mentary Table 5 indicates targets for the sRNAs) [11–14]. These
modiﬁcations were incorporated to potentially increase the pro-
duction of conserved outer membrane proteins which may  enhance
the immune response of vaccinated animals. Therefore, it is pro-
posed that the attenuated BBS 866 strain provides at least two
advantages for vaccination: decreased production of the immuno-
dominant and highly variable Salmonella O-antigen and increased
production of Salmonella-conserved outer membrane proteins.
This vaccination strategy is designed to provide enhanced cross-
protection against a broad repertoire of Salmonella serovars to
which the animal may  be exposed during its lifetime.
In conjunction with other swine management tools includ-
ing effective biosecurity, vaccination against Salmonella may assist
in the protection of animal health, reduction of antibiotic usage,
enhancement of food safety, diminution of economic losses,
and alleviation of environmental risk. However, there are >2500
Salmonella serovars that differ in part due to immunodominant
antigens such as LPS and ﬂagella; in fact these antigens are the
basis for Salmonella serovar differentiation by phage typing. Unfor-
tunately, the antigenic complexity of the Salmonella genus may
reduce the ability of the host immune response to cross-protect
against multiple Salmonella serovars. An immune response to
immunodominant antigens in a serovar-speciﬁc manner that pro-
vides poor cross-protection against other serovars is a type of
deceptive imprinting [15]. The Salmonella genus has mastered
this immune evasion technique with multiple reports highlight-
ing that serovar cross-protection is often lower compared to a
serovar-speciﬁc immune response [16–18]. RfaH is an antiter-
minator that enhances transcription elongation of long operons
including genes encoding biosynthesis of LPS [19]. The deletion
of rfaH in our vaccine strain decreases the immunodominant LPS
antigen as shown in the ELISA assay by the inability to detect
an increase in porcine anti-Salmonella LPS antibodies following
vaccination. The reduction of LPS in the rfaH mutant allows for
the differentiation of infected from vaccinated animals (DIVA)
and therefore can be used in conjunction with herd level mon-
itoring of Salmonella status. Furthermore, the decrease in the
serovar Typhimurium immunodominant LPS antigen in our vac-
cine strain should facilitate refocusing of the immune response
to Salmonella-conserved antigens including outer membrane pro-
teins [15]. The immune refocusing affords cross-protection against
non-Typhimurium serovars including S. Choleraesuis. Indeed, vac-
cination with either S. Typhimurium BBS 202 or BBS 866 provided
cross-protection against challenge with wild-type S. Cholerae-
suis for multiple clinical and bacteriological parameters. Mutation
of multiple sRNAs in BBS 866 further enhanced cross-protection
against S. Choleraesuis challenge. The cross-protection of BBS 866
has also been extended to challenge with multidrug-resistant S.
Heidelberg in turkeys where vaccination signiﬁcantly reduced both
the CFU of S. Heidelberg recovered from the spleen and the number
of spleens from which S. Heidelberg could be recovered (unpub-
lished results). Therefore, the BBS 866 vaccine strain overcomes
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